anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Young children with Type 1 Diabetes (T1D) in the age range of 5-8 years old are a population with clear needs but unique challenges regarding the application of artificial pancreas (AP) technologies. Young children are likely to benefit from an AP system, with current deficits in glycemic control that include both significant hypoglycemia and sub-optimal HbA1c levels; however, they have undeveloped abilities to control and interact with the AP system, posing potential safety issues. During the hours that these children are away from their parents at school and elsewhere, they lack the sophistication to operate the currently-available tools in an AP system--and may induce harm if they are allowed to do so, causing parental resistance to AP use. Commercially-available insulin pumps have mechanisms to lock access to children to prevent inappropriate insulin-delivery. However, the AP is more complex than an insulin pump, both in requiring more detailed setting information (that a child could adversely alter) and in providing alerts for impending low- and high-blood glucose (BG) levels (that one wouldn't want to lock out to child use). These functions are all run via a platform on a smart phone-a device with which young children may already feel a high degree of familiarity and thus be more likely to attempt to explore and potentially change settings. It is likely that young children will benefit the most from a system that gives them access to some AP features but provides access to other features only for their parents. In this sense, young children require a device that is not user-centered as much as family-centered. A redesign of the system to provide appropriate access to AP tools-in which certain users can obtain access to certain functionalities-is direly needed before children in this age range can benefit from the improvements in blood glucose (BG) control that the AP has to offer.
A negative pressure therapy (Kinetic Concepts, Inc, San Antionio, Tex) device will be applied under sterile conditions post-operatively and placed on suction (125-150 cm H2O). The device will be removed on post-operative day 4-7 depending on day of discharge.
PROBLEM TO BE SOLVED: To obtain the subject preparation useful as an antiallergic medicine exhibiting an antihistamic action in the form of a dry syrup not discolored with tap water by adding a specific compound. SOLUTION: This mequitazine preparation is obtained by adding <=3 pts.wt. of citric acid or succinic acid to mequitazine and subsequently processing the mixture into a dry syrup. The citric acid or succinic acid includes their anhydrides and salts, such as citric anhydride, citric acid hydrate, sodium citrate, potassium citrate, succinic anhydride, sodium succinate and potassium succinate. One of the compounds may be used, or two or more of the compounds may simultaneously be used. The dry syrup is obtained by adding the mixture of the mequitazine with additives (a sugar, a flavor, a sweetener, etc.), to the 50% ethanol solution of the citric acid or succinic acid, kneading the mixture and subsequently drying the kneaded product.
Patients with severely impaired renal function have been treated with cimetidine tablets. However, such usage has been very limited. On the basis of this experience the recommended dosage is 300 mg every 12 hours orally. Should the patient’s condition require, the frequency of dosing may be increased to every 8 hours or even further with caution. In severe renal failure, accumulation may occur and the lowest frequency of dosing compatible with an adequate patient response should be used. When liver impairment is also present, further reductions in dosage may be necessary. Hemodialysis reduces the level of circulating cimetidine. Ideally, the dosage schedule should be adjusted so that the timing of a scheduled dose coincides with the end of hemodialysis.
Sleep, circadian rhythms, and mental health are reciprocally interlinked. Disruption to the quality, continuity, and timing of sleep can precipitate or exacerbate psychiatric symptoms in susceptible individuals, while treatments that target sleep-circadian disturbances can alleviate psychopathology. Conversely, psychiatric symptoms can reciprocally exacerbate poor sleep and disrupt clock-controlled processes. Despite progress in elucidating underlying mechanisms, a cohesive approach that integrates the dynamic interactions between psychiatric disorder with both sleep and circadian processes is lacking. This review synthesizes recent evidence for sleep-circadian dysfunction as a transdiagnostic contributor to a range of psychiatric disorders, with an emphasis on biological mechanisms. We highlight observations from adolescent and young adults, who are at greatest risk of developing mental disorders, and for whom early detection and intervention promise the greatest benefit. In particular, we aim to a) integrate sleep and circadian factors implicated in the pathophysiology and treatment of mood, anxiety, and psychosis spectrum disorders, with a transdiagnostic perspective; b) highlight the need to reframe existing knowledge and adopt an integrated approach which recognizes the interaction between sleep and circadian factors; and c) identify important gaps and opportunities for further research.
Recombinant adeno-associated viruses are described. The recombinant adeno-associated virus may comprise capsid proteins having enhanced hepatocyte targeting. The recombinant adeno-associated virus exhibits reduced immunogenicity in humans. The recombinant adeno-associated virus may comprise an expression cassette comprising a polynucleotide sequence encoding a therapeutic agent for treating a liver disease. The invention also provides a packaging system of the recombinant adeno-associated virus and a method for producing the recombinant adeno-associated virus. Pharmaceutical compositions comprising recombinant adeno-associated virus and the use of said compositions for the treatment of liver diseases including fabry disease and hepatitis b.
During the metastatic cascade, cancer cells travel through the bloodstream as circulating tumor cells (CTCs) to a secondary site. Clustered CTCs have greater shear stress and treatment resistance, yet their biology remains poorly understood. We therefore engineered a tunable superhydrophobic array device (SHArD). The SHArD-C was applied to culture a clinically relevant model of CTC clusters. Using our device, we cultured a model of cancer cell aggregates of various sizes with immortalized cancer cell lines. These exhibited higher E-cadherin expression and are significantly more capable of surviving high fluid shear stress-related forces compared to single cells and model clusters grown using the control method, helping to explain why clustering may provide a metastatic advantage. Additionally, the SHArD-S, when compared with the AggreWell 800 method, provides a more consistent spheroid-forming device culturing reproducible sizes of spheroids for multiple cancer cell lines. Overall, we designed, fabricated, and validated an easily tunable engineered device which grows physiologically relevant three-dimensional (3D) cancer models containing tens to thousands of cells.
Hypercoagulability and reduced fibrinolysis are well-established complications associated with COVID-19. However, the timelines for the onset and resolution of these complications remain unclear. The aim of this study was to evaluate, in a cohort of COVID-19 patients, changes in coagulation and fibrinolytic activity through ROTEM assay at different time points during the initial 30 days following the onset of symptoms in both mild and severe cases. Blood samples were collected at five intervals after symptoms onset: 6-10 days, 11-15 days, 16-20 days, 21-25 days, and 26-30 days. In addition, fibrinogen, plasminogen, PAI-1, and alpha 2-antiplasmin activities were determined. Out of 85 participants, 71% had mild COVID-19. Twenty uninfected individuals were evaluated as controls. ROTEM parameters showed a hypercoagulable state among mild COVID-19 patients beginning in the second week of symptoms onset, with a trend towards reversal after the third week of symptoms. In severe COVID-19 cases, hypercoagulability was observed since the first few days of symptoms, with a tendency towards reversal after the fourth week of symptoms onset. A hypofibrinolytic state was identified in severe COVID-19 patients from early stages and persisted even after 30 days of symptoms. Elevated activity of PAI-1 and alpha 2-antiplasmin was also detected in severe COVID-19 patients. In conclusion, both mild and severe cases of COVID-19 exhibited transient hypercoagulability, reverted by the end of the first month. However, severe COVID-19 cases sustain hypofibrinolysis throughout the course of the disease, which is associated with elevated activity of fibrinolysis inhibitors. Persistent hypofibrinolysis could contribute to long COVID-19 manifestations.
Familial cases are defined as patients diagnosed for sarcoidosis with a first and/or second degree relative parent also affected by a well-proven sarcoidosis syndrome. More than 70% of SARCFAM families included two first-degree affected individuals, with both a vertical or horizontal transmission. The Mendelian trait seems to be autosomal dominant. 20 to 30% of the families consists of 3, 4 or more cases, with a subset of families including more than 5 cases. Patients are managed as for the sporadic one, and in such families, an informed consent was also provided with a clear explanation on the complexity of the genetic background of the disease. In blood samples, genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING will be done.
The invention provides stable tretinoin tablets. Every 1000 tretinoin tablets are prepared from the following components: 10g of tretinoin, 80g of lactose, 50g of pregelatinized starch, 50g of dextrin, 2g of magnesium stearate, 0.02g of butylated hydroxyanisole (BHA), 0.02g of butylated hydroxytoluene (BHT) and right amount of 10% polyvinyl pyrrolidone (PVP) ethanol solution. Composite antioxidants (0.01% of BHA and 0.01% of BHT) are added into the formula to inhibit the decreased content of tretinoin due to oxidization. An aluminum-plastic blister package (the medicine package uses aluminum foils and polyvinyl chloride (PVC) plastic hard sheets) is adopted, a polyester/aluminum/polyethylene medicinal composite film bag is coated outside, and vacuum anaerobic packaging is carried out. The packaging mode is optimized to achieve the effect of isolating external oxidizing sources and effectively prevent the main drug tretinoin from oxidative degradation, thereby providing the stable tretinoin tablets and a preparation method thereof. The invention ensures the stability of the product quality, is suitable for industrial production, and has high application value.
The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
The present invention relates to a device and method which can deliver a drug to an entire epithelial surface of the nasal cavity and nasopharynx to eliminate microorganisms which are attached to the epithelial surface of the nasal cavity and nasopharyngeal, inhabit, or reproduce. Provided are a device and method for administering a drug to the nasal cavity and nasopharynx. According to the present invention, a device containing liquid is placed in the nostrils of a subject to communicate with the nasal cavity. The face is raised high so that a gaze is at 20 to 90 degrees and nasal breathing is blocked. The drug is filled into a nasal cavity and nasopharyngeal space through the nostrils in an isolated space created between the nasal cavity and nasopharynx. In addition, by shaking the filled drug, the drug can be sufficiently delivered to the epithelial surface of the nasal cavity and nasopharyngeal. Accordingly, an absorption rate of the drug can be increased.
Subjects will be assigned to any of the 4 dosage regimen (A, B, C, D) in four periods. A= GSK2190915 Solution, 50mg single dose, fasted; B = GSK2190915 Capsule Formulation A, 50mg single dose (1 x 50mg capsule), fasted; C= GSK2190915 Capsule Formulation B, 50mg single dose (1 x 50mg capsule), fasted; D= GSK2190915 Capsule Formulation C, 50mg single dose (1 x 50mg capsule), fasted.
The present invention provides a method of treating or preventing hyperlipidemia in a subject in need thereof. Such method includes, specifically, administrating to the subject a therapeutically effective amount of a caffeamide derivative. The present invention also provides a pharmaceutical composition containing, primarily, the caffeamide derivative. The method and pharmaceutical composition of the present invention can effectively and significantly lower the high-fat diet-induced body weight gain and absolute visceral fat weight as well as the concentration of triglycerides and free fatty acids in blood, and levels of total lipid and triacylglycerol in liver tissue. In addition, the caffeamide of the present invention also reduces size of adipocyte, hepatocellular ballooning phenomenon, and liver steatosis. Through promotion of phosphorylation of 5′ adenosine monophosphate-activated protein kinase (AMPK) in muscle and liver, the caffeamide derivatives of the present invention is suitable for ameliorating or remedying hyperlipidemia.
NEW MATERIAL:A compound of formulaI(R is 1-10C chain alkyl; dotted line represents single or double bond). EXAMPLE:5H-2,3,6,7-Tetrahydro-6-methyl-5,7-dioxothiazolo[3,2-a]pyrimid ine. USE:It is used as a remedy for autoimmune diseases such as nephritis or rheumatoid arthritis or for malignant tumors. PREPARATION:The condensation cyclization reaction between a malonic acid derivative of formula II (R<1> and R<2> are lower alkyl) and 2-aminothiazoline or 2-aminothiazole is conducted in the presence of an alkali metal alkoxide to give the compound of formulaI. The product is contained as an active ingredient to form the objective immunoregulator. It is given orally or parenterally, e.g., intravenously, rectally, intracutaneously or intramuscularly.
Frailty is an important public health concern associated with aging. It increases the risk of adverse clinical outcomes, such as falls, late-life dependency, hospitalization, disability, and mortality. The objectives of this study were to estimate the prevalence of frailty and to identify factors associated with frailty among older adults (≥65 years) admitted to King Abdulaziz University Hospital, Jeddah, Saudi Arabia. This cross-sectional study was conducted at King Abdulaziz University Hospital. The data were collected during the months of January and February 2022 and included demographic characteristics, comorbidities, length of stay, and hospital mortality. Frailty status of participants was assessed using the Clinical Frailty Scale. A total of 147 patients (aged ≥ 65 years) were included in our study. The prevalence rates of frailty and non-frailty were 71.4% and 28.6%, respectively. Frail patients had higher comorbidity index (P = .003), polypharmacy (P = .003), heart failure (P = .001), and prolonged hospital stays (P = .007). The results of the multiple logistic regression revealed that the tall patients had a lower risk of frailty (odds ratio = 0.0089, 95% confidence interval: 0.0001-0.7588, P = .042) and patients with higher comorbidity indexes had higher risk of frailty (odds ratio = 1.4907, 95% confidence interval: 1.1449-1.9927, P = .004). In this study, more than two-thirds of the hospitalized older patients were classified as frail. High comorbidity index, heart failure, and polypharmacy were strong predictors of frailty. Patients with frailty were more likely to have a prolonged hospital stay than those without frailty. Therefore, early detection of frailty and proper intervention are essential for improving health outcomes in this vulnerable population.
A computing server may use one or more recommender systems to predict phenotypes of individuals based on survey responses, other phenotypes, environmental factors, and genetic data of the individuals. The computing server may retrieve survey responses of a set of individuals regarding a set of phenotypes of the individuals. The computing server may construct a matrix that includes the values of the phenotypes. The computing server may predict an undetermined phenotype of a target individual using collaborative filtering, which provides the prediction based on other phenotypes of the target individuals and based on at least another individual's phenotypes. The computing server may also predict a target phenotype based on the phenotype of other individuals who are similar to the target individual. The computing server may determine another individual is similar to the target individual based on the length of identity-by-descent (IBD) segments between the two individuals.
Because the contraceptive effect of Skyla is mainly due to its local effects within the uterus, ovulatory cycles with follicular rupture usually occur in women of fertile age using Skyla. Ovarian cysts (reported as adverse reactions if they were abnormal, non-functional cysts and/or had a diameter >3 cm on ultrasound examination) were reported at least once over the course of clinical trials in 13.2% of women using Skyla, and 0.3% of subjects discontinued because of an ovarian cyst. Most ovarian cysts are asymptomatic, although some may be accompanied by pelvic pain or dyspareunia. In most cases the ovarian cysts disappear spontaneously during two to three months observation. Evaluate persistent ovarian cysts. Surgical intervention is not usually required.
Our primary objective is initiating a personalized approach to curative therapies in children and adults with sickle cell disease (SCD) to maximize benefits and limit adverse outcomes. Limited clinical studies exist to determine the long-term health outcomes following curative therapies for SCD. With emerging curative therapies for SCD (allogeneic \[allo\] hematopoietic stem cell transplant \[HSCT\], gene therapy/editing), long-term health outcomes studies are critical to inform personalized choices. Unfortunately, adverse outcomes have started to emerge after SCD curative therapy. Thus, risks of a cure in SCD must be measured against the benefits of a cure, including stabilization of lung function (FEV1) and improved tricuspid regurgitant jet velocity \[TRJV\]. Ultimately, the shortened lifespan of individuals with SCD, attributable to declining heart (elevated TRJV), lung (decreased FEV1), and kidney (decreased eGFR) function, for which curative therapies were designed to ameliorate, must be measured against favorable and unfavorable late outcomes. In our multicenter retrospective-prospective cohort, the investigators will test the following hypotheses: 1a): myeloablative curative therapies for children with SCD will result in progressive pulmonary and renal dysfunction when compared to children with SCD receiving standard therapy; 1b): nonmyeloablative HSCT for adults with SCD will result in no significant change in FEV1% predicted, but will lead to accelerated decline in eGFR when compared to adults receiving standard therapy; 2) nonmyeloablative HSCT for adults with SCD will be associated with a clinically significant improvement in TRJV following HSCT; and 3) in adults with SCD, proliferative and genotoxic stress uniformly related to nonmyeloablative allo-HSCT and myeloablative gene editing will lead to post-HSCT therapy-related myeloid neoplasm of recipient origin. The investigators will address these hypotheses with the following aims: 1) evaluate the incidence of pulmonary and renal function in 1a: children with SCD receiving myeloablative curative therapies; and 1b: adults with SCD receiving nonmyeloablative allo-HSCT, compared to a pre-existing cohort of children and adults with SCD; 2) determine whether there is a clinically significant improvement in TRJV in adults with SCD, at least half having TRJV \> 2.5 m/s, following nonmyeloablative allo-HSCT, 3) evaluate the prevalence, incidence and evolution of Clonal hematopoiesis of indeterminate potential (CHIP) concerning therapy-related myeloid neoplasm development following non-myeloablative HSCT or myeloablative gene editing in adults and children with SCD, and 4) evaluate accuracy and gaps involved in collecting clinical health record data directly from patients and family members in comparison to clinical health record data collected by research coordinators.
JNJ-40411813 is a positive allosteric modulator (PAM) of the metabotropic glutamate receptor-2 (mGlu2), which is abundantly expressed in the forebrain and cerebellum. The mGlu2 receptor functions as a presynaptic auto-receptor that, upon activation, decreases the release of the excitatory neurotransmitter glutamate. Positive allosteric modulation of a receptor will result in the direct enhancement of the agonist-induced signal while PAMs themselves have generally no or low intrinsic activity at the receptor. The net effect of JNJ-40411813 is hypothesized to be a normalization of hyper-glutamatergic transmission. JNJ-40411813 is being evaluated for the treatment of disorders of the central nervous systems (CNS), such as epilepsy, and has been evaluated in schizophrenia and anxious depression. This study will consist of 1 to a maximum of 3 cohorts. In each cohort, for each participant the study consists of a screening period (up to minus \[-\] 8 weeks), an 8-week prospective pretreatment baseline period, an up to 12-week double-blind treatment period and a 2-year OLE period or a follow-up telephone visit 2 weeks after the last dose of study intervention. Safety assessments including physical and neurological examination, vital signs, 12 lead electrocardiogram (ECG), clinical chemistry, hematology, and urinalysis will be performed. The total maximal duration of the study is up to 2 years and 5 months.
This is an open-label, multi-centre, flexible dose study of retigabine immediate release (IR). The study will enroll male and female outpatients (≥ 18 years of age) with partial-onset seizures (POS) who are inadequately controlled on their current monotherapy Antiepileptic Drug (AED). Following a Screening Period of up to 2 weeks, subjects will enter an 8-week Baseline Phase to determine baseline seizure frequency. At the end of the Baseline Phase, subjects who meet or exceed the minimum seizure frequency of 4 partial seizures per 56 days, will enter the Treatment Period (4 weeks Titration, 16 weeks Flexible Dose Evaluation Phase). All subjects will receive retigabine IR starting at 150 mg/day and will be titrated to 600 mg/day by Week 4. From Week 5 onwards, subjects' doses will be maintained between 300 to 1200 mg/day using a flexible dosing regimen to optimise response and tolerability. The maximum duration of the study is approximately 33 weeks (inclusive of a 3 week Taper/Follow-up Phase).
423,741. Hair - waving processes. STRONG, J. N., 3, Barston Road, West Norwood, London. Aug. 2, 1933, No. 21690. [Class 131] A process of permanent hair-waving comprises impregnating the tresses with an aqueous emulsion of a mineral or vegetable oil and an alkali borate, sulphite, carbonate or hydroxide, either before or after winding the tresses on the curlers, and then applying heat thereto. The mineral oil may be either of the paraffin or asphaltic type, and suitable vegetable oils are olive, linseed, maize or cotton seed oil. Gelatine, agar agar, Irish moss or triethanolamine may be used as the emulsifying agent.